BR0306984A - Pim-3 quinase como alvo para diabetes melito tipo 2 - Google Patents

Pim-3 quinase como alvo para diabetes melito tipo 2

Info

Publication number
BR0306984A
BR0306984A BR0306984-2A BR0306984A BR0306984A BR 0306984 A BR0306984 A BR 0306984A BR 0306984 A BR0306984 A BR 0306984A BR 0306984 A BR0306984 A BR 0306984A
Authority
BR
Brazil
Prior art keywords
pim
type
diabetes mellitus
kinase targeted
nucleic acid
Prior art date
Application number
BR0306984-2A
Other languages
English (en)
Inventor
Marcus Korn
Guenter Mueller
Rudolf Schneider
Georg Tschank
Original Assignee
Aventis Pharma Deutschaland Gm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschaland Gm filed Critical Aventis Pharma Deutschaland Gm
Publication of BR0306984A publication Critical patent/BR0306984A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PIM-3 QUINASE COMO ALVO PARA DIABETES MELITO TIPO 2". A presente invenção refere-se a moléculas de ácido nucléico isoladas e a células hospedeiras que compreendem tais moléculas de ácido nucléico. Além disso, a invenção refere-se a um polipeptídeo que apresenta atividade de PIM-3 e tem uma seq³ência de aminoácidos definida, bem como ao uso de PIM-3 como agente de seleção para identificar drogas anti-diabetes melito tipo 2 e para preparar um medicamento para o tratamento de resistência à insulina ou diabetes melito tipo 2.
BR0306984-2A 2002-01-19 2003-01-20 Pim-3 quinase como alvo para diabetes melito tipo 2 BR0306984A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02001401 2002-01-19
PCT/EP2003/000492 WO2003060130A2 (en) 2002-01-19 2003-01-20 Pim-3 kinase as a target for type 2 diabetes mellitus

Publications (1)

Publication Number Publication Date
BR0306984A true BR0306984A (pt) 2004-12-14

Family

ID=8185311

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0306984-2A BR0306984A (pt) 2002-01-19 2003-01-20 Pim-3 quinase como alvo para diabetes melito tipo 2

Country Status (14)

Country Link
EP (1) EP1468092B1 (pt)
JP (1) JP4272533B2 (pt)
KR (2) KR101158326B1 (pt)
CN (1) CN100467601C (pt)
AT (1) ATE541040T1 (pt)
BR (1) BR0306984A (pt)
CA (2) CA2473566C (pt)
DK (1) DK1468092T3 (pt)
IL (1) IL194074A (pt)
MX (1) MXPA04006906A (pt)
NO (1) NO333253B1 (pt)
RU (1) RU2316598C2 (pt)
WO (1) WO2003060130A2 (pt)
ZA (1) ZA200404997B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096833A1 (en) * 2003-08-11 2008-04-24 Naofumi Mukaida Polytpeptide Specific To Liver Cancer, Polynucleotide Coding For The Polypeptide, And Rna Molecule Inhibiting Expression Of The Polypeptide
US20220235343A1 (en) * 2019-06-27 2022-07-28 Industrial Cooperation Foundation Chonbuk National University Novel adp-ribosyl cyclase and inhibitor thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0911391A3 (en) * 1997-10-24 2000-01-19 Smithkline Beecham Corporation A clone HWHHJ20
US6143540A (en) * 1999-01-26 2000-11-07 Millennium Pharmaceuticals, Inc. Molecules of the HKID-1-related protein family and uses thereof
CN1328134A (zh) * 2001-04-13 2001-12-26 复旦大学 一种蛋白激酶编码序列,其编码的多肽、制法及用途
DE10123055A1 (de) * 2001-05-11 2003-03-20 Gruenenthal Gmbh Screeningverfahren mit PIM1-Kinase oder PIM3-Kinase

Also Published As

Publication number Publication date
CA2680946C (en) 2013-03-12
KR101158326B1 (ko) 2012-06-28
CA2473566A1 (en) 2003-07-24
JP2005514068A (ja) 2005-05-19
JP4272533B2 (ja) 2009-06-03
KR101205194B1 (ko) 2012-11-27
ATE541040T1 (de) 2012-01-15
RU2316598C2 (ru) 2008-02-10
CA2473566C (en) 2012-05-01
ZA200404997B (en) 2006-05-31
NO333253B1 (no) 2013-04-22
WO2003060130A3 (en) 2004-01-15
DK1468092T3 (da) 2012-05-07
CA2680946A1 (en) 2003-07-24
KR20040075940A (ko) 2004-08-30
AU2003202579A1 (en) 2003-07-30
EP1468092A2 (en) 2004-10-20
MXPA04006906A (es) 2004-12-06
CN1620505A (zh) 2005-05-25
EP1468092B1 (en) 2012-01-11
WO2003060130A2 (en) 2003-07-24
RU2004125291A (ru) 2005-04-20
NO20043459L (no) 2004-10-07
CN100467601C (zh) 2009-03-11
IL194074A (en) 2011-08-31
KR20110011753A (ko) 2011-02-08

Similar Documents

Publication Publication Date Title
BRPI0519241A2 (pt) agonistas, composiÇÕes, mÉtodos e usos de glp-1
BRPI0508455A (pt) muteìnas de interleucina-2 combinatórias
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
TW200744642A (en) Novel peptides for use in the treatment of obesity
BRPI0508068A (pt) moléculas de ácido nucléico isoladas, vetor compreendendo as mesmas, polipeptìdeos isolados e composições compreendendo os mesmos
EA200702093A1 (ru) Антитела-миметики glp-1 человека, композиции, способы и их применение
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
DK2016102T3 (da) Kimære T-cellereceptorer og tilhørende materialer og fremgangsmåder til anvendelse
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
NO20055209D0 (no) Peptabody for cancerbehandling
BRPI0416434A (pt) métodos para aumentar a atividade de uma proteìna de ácido esfingomielinase (asm), para estender a meia-vida e prolongar a atividade de uma proteìna asm purificada, para aumentar a produção de uma proteìna asm recombinante através de uma célula hospedeira, e usos de uma composição de asm tipo alelo-selvagem, purificada e um composto análogo de ceramida ou esfingomielina, e de um composto análogo de ceramida ou de esfingomielina
NO20020470D0 (no) Polymorfier i det humane MDR-1-genet og deres anvendelse i diagnostisk og terapeutiske anvendelser
TW200724679A (en) Treatment of disease using an improved regulated expression system
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
BR0306984A (pt) Pim-3 quinase como alvo para diabetes melito tipo 2
NO20021147D0 (no) Polymorfismer i det humane hPXR-genet og deres anvendelse i diagnostiske og terapeutiske applikasjoner
ATE340573T1 (de) Verwendung von 7-nitro-2,1,3-benzoxadiazol derivaten zur behandlung von krebserkrankungen
DE602005021159D1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
NO20081541L (no) Ny sjo-lus vaksine
TW200716749A (en) Interferon-beta gene therapy using an improved, regulated expression system
BRPI0409948A (pt) composições de spex e processos de uso
ATE464070T1 (de) Iniizierbares mittel zur zielgerichteten behandlung von retinalen ganglienzellen
BRPI0415296A (pt) cdna modificado para os nìveis de expressão elevados do fator viii e seus derivados
ATE407944T1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
BRPI0407333A (pt) Uso de antagonistas do receptor b2 de bradiquinina para o tratamento de osteoartrose

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]